X

Trial Profile

Pegylated Interferon +/- Ribavirin for Children With Hepatitis C.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
Indications Hepatitis C
Focus Registrational; Therapeutic Use
Acronyms PEDS-C

Most Recent Events

21 Mar 2013 Based on the results of this trial, Pegasys received EU approval for the treatment of chronic hepatitis C in children and adolescents aged ≥5 years, according to a Roche media release.
02 Mar 2012 Results published in Hepatology.
08 Nov 2011 Results from a longitudinal evaluation relating adiponectin levels to treatment presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com